OKYO Pharma Limited has filed its annual report on Form 20-F for the fiscal year ended March 31, 2026, with the US Securities ...
At ASRS 2026, the dual inflammasome inhibitor K8 slowed geographic atrophy lesion growth by up to 54% over 6 months in a phase 2 trial and showed a visual acuity advantage in eyes with extrafoveal ...
Louie Cai, MD: Manual prescreening for clinical trials is very labor intensive, taking as long as 30 minutes to an hour per ...
The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment ...
Danon disease has been misclassified as cone dystrophy, cone-rod dystrophy, or retinitis pigmentosa; distinguishing features include the absence of optic disc pallor, bone-spicule pigmentation, and a ...
Two-year PRISM results show 4D-150 gene therapy sustains wet AMD vision while cutting anti-VEGF injections up to 87%, with ...
Microsecond green laser (520 nm; Norlase) improved visual acuity and reduced macular thickness in eyes with chronic central ...
Awh, MD, FASRS, presented 2-year data at ASRS 2026 showing 4D-150 gene therapy cut anti-VEGF injection burden in wet AMD, ...
Bausch + Lomb’s EyeGility preloaded enVista IOL inserter streamlines cataract surgery with push-plunger delivery, less handling, faster workflow. Bausch + Lomb has announced the US commercial launch ...
PRIMA, the first brain-computer interface approved for form vision restoration (reading letters, numbers, words) in patients with geographic atrophy (GA) secondary to age-related macular degeneration, ...
OPTIC data showed a single injection of Ixo-vec gene therapy cut annualized anti-VEGF injections 87%, with sustained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results